The Targeted Pulse
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
3
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
4
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
5
